CheqUp and WeightWatchers Unite for Comprehensive Weight Loss Solutions
CheqUp and WeightWatchers partner to enhance weight loss efforts through GLP-1 medications and behavioral support services.
Overview of the Partnership
CheqUp, a leading UK provider of GLP-1 weight loss services, has formed a partnership with WeightWatchers to improve weight management for patients using GLP-1 medications. This collaboration merges CheqUp’s personalized clinical support and live health coaching with WeightWatchers’ GLP-1 Companion Programme, offering customized nutritional and behavioral lifestyle guidance. This initiative is focused on enhancing weight loss outcomes for approximately 12 million individuals in the UK eligible for GLP-1 treatments. By combining medication with behavioral changes, the partnership promotes sustainable weight loss.
Advantages of the Collaboration
- CheqUp benefits from WeightWatchers’ established reputation in weight management, boosting its credibility and service offerings.
- The alliance meets a significant market demand, potentially reaching 12 million individuals in the UK who may benefit from integrated GLP-1 medication and behavioral support, hence broadening CheqUp’s customer base.
- Members of CheqUp will access enhanced WeightWatchers resources at no extra cost, aiding their weight loss journey.
- This collaboration emphasizes a comprehensive care model, likely leading to better weight loss results compared to relying on medication alone.
Challenges to Consider
- Concerns may arise regarding potential dependency on GLP-1 medications, as the focus on combined treatment could raise questions about the long-term sustainability of weight loss achievements.
- The partnership might suggest that CheqUp depends on a well-known brand like WeightWatchers to improve its offerings, which could imply limitations in its own service capabilities.
- As demand for GLP-1 medications grows, CheqUp may face increased competition within a swiftly changing market.
Frequently Asked Questions
What does the partnership between CheqUp and WeightWatchers entail?
The partnership aims to combine GLP-1 medication with behavioral support for more sustainable weight loss.
How will patients benefit from this partnership?
It provides an integrated approach, merging clinical support with nutritional and behavioral guidance for those on GLP-1 medications.
What resources will CheqUp members gain from WeightWatchers?
Members will receive nutritional guidance, tracking tools, support groups, and a comprehensive progress overview at no additional cost.
Why is demand for GLP-1 medications increasing in the UK?
Rising health awareness and the search for effective weight management options are driving the demand for GLP-1 medications in the UK.
What outcomes can members expect from the combined programs?
Members typically experience greater weight loss when utilizing both medication and behavioral support, promoting long-term success in weight management.
$WW Hedge Fund Activity
In recent quarters, 31 institutional investors have added shares of $WW while 67 have decreased their positions.
- POINT72 ASSET MANAGEMENT, L.P. removed 1,050,295 shares (-100.0%) in Q1 2025, valued at $548,884.
- TWO SIGMA ADVISERS, LP removed 847,300 shares (-100.0%) in Q4 2024, valued at $1,076,071.
- UBS GROUP AG added 698,600 shares (+559.2%) in Q1 2025, valued at $365,088.
- MILLENNIUM MANAGEMENT LLC added 580,088 shares (+659.6%) in Q1 2025, valued at $303,153.
- SHENKMAN CAPITAL MANAGEMENT INC removed 557,118 shares (-100.0%) in Q1 2025, valued at $291,149.
- ARISTEIA CAPITAL, L.L.C. removed 523,815 shares (-100.0%) in Q1 2025, valued at $273,745.
- JPMORGAN CHASE & CO removed 466,914 shares (-99.6%) in Q1 2025, valued at $244,009.
Full Release
CHIPPENHAM, England, May 22, 2025 (GLOBE NEWSWIRE) — CheqUp, a leading UK provider of GLP-1 based weight loss services, and WeightWatchers, a global leader in science-backed weight management, have announced a partnership to benefit patients seeking sustainable weight loss through GLP-1 medication and behavioral support.
This partnership delivers a seamless solution that combines:
- CheqUp’s human-centric approach to supporting prescribed weight loss medication with dedicated clinical support and live, one-to-one health coaching.
- WeightWatchers’ industry-leading GLP-1 Companion Programme, providing tailored nutritional and behavioral lifestyle support for individuals on GLP-1 medications.
Together, these offerings provide a more effective solution to weight management, assisting members in achieving better results than with medication alone.
With 12 million people in the UK qualifying for prescription GLP-1 medications, this partnership addresses the increasing market demand by offering a holistic care model for those currently on, or considering, GLP-1 treatment. The UK Government is already examining the case for a wider rollout of GLP-1 medications, recognizing their potential to improve health and impact productivity.
“We are pleased that WeightWatchers has chosen CheqUp as its strategic partner in the GLP-1 category,” stated James Hunt, Deputy CEO of CheqUp. “Our growth reflects the increasing number of individuals opting for CheqUp’s support during the challenging but rewarding journey of weight loss. The integration of WeightWatchers’ GLP-1 Companion Programme will significantly enhance our patients’ ability to achieve sustainable weight loss, utilizing their proven systems and supportive community.”
WeightWatchers Launches GLP-1 Companion Program with CheqUp
WeightWatchers has teamed up with CheqUp to introduce a new GLP-1 Companion Program designed to enhance weight management for users of GLP-1 obesity medications. This collaboration recognizes the increasing demand for effective weight loss solutions, particularly in the UK market.
According to Scott Honken, Chief Commercial Officer at WeightWatchers, data shows that U.S. members on obesity medications who also take part in nutrition and behavioral programs lose 11% more weight on average than those who only use the medication. “When medication is part of the journey, it’s the combination with behavioral support that leads to more sustainable, superior results,” he stated.
Features of the GLP-1 Companion Program
CheqUp members will gain access to valuable tools and resources through this initiative:
- Nutritional Guidance: Members will receive expert recommendations for nutrient-dense foods that minimize side effects and promote effective weight loss.
- Simple Tracking Experience: A streamlined system will allow users to monitor daily nutrition targets, including protein, fruits and vegetables, and hydration.
- Judgment-Free Support: Members can engage with WeightWatchers’ exclusive social network groups to share insights and receive encouragement from others on similar journeys.
- Comprehensive Progress Overview: Users will be able to track weight loss, identify trends, and create actionable plans for future success.
This program is available at no cost to CheqUp members actively participating in weight loss efforts with GLP-1 medications.
WeightWatchers’ Legacy
With over 60 years of experience, WeightWatchers continues to lead in weight management. The program’s holistic, science-backed approach combines personalized support with evidence-based behavioral tools. A recent study of 3,260 WeightWatchers Clinic patients in the U.S. reported an average weight loss of 21% over 12 months, illustrating the effectiveness of its methods.
About CheqUp
CheqUp provides medically supervised weight loss programs, offering tailored treatment plans and clinical oversight. Their mission is to empower individuals to take control of their health using accessible and evidence-based solutions.
About WW International, Inc.
WeightWatchers is recognized as a leader in science-backed weight management, providing an accessible, holistic care model through its widely used Points® Program and community support. Since its inception in 1963, WeightWatchers has helped millions build healthy habits for longer, healthier lives.
This article was originally published on Quiver News. Read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
